Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule drugs targeting G-protein coupled receptors (GPCRs). The company has no approved products or product revenue. Its lead program is aleniglipron (GSBR-1290), an oral GLP-1 receptor agonist for obesity and overweight adults with related comorbidities. The core thesis is that an oral pill can deliver weight loss comparable to injectable GLP-1R agonists like Wegovy and Zepbound, but with better convenience and adherence. Aleniglipron completed Phase 2b with placebo-adjusted weight loss of 11.3% at 36 weeks at the 120 mg dose, and an exploratory higher-dose study showed 15.3% at 240 mg. Structure Therapeutics plans an End-of-Phase 2 FDA meeting and expects to start Phase 3 in the second half of 2026. Beyond aleniglipron, the company is building a metabolic franchise by advancing oral amylin receptor agonists (ACCG-2671 entered Phase 1 in late 2025) and earlier-stage GIPR and glucagon receptor programs, with the goal of combining these into fixed-dose pills targeting obesity, T2DM, and cardiovascular conditions. Structure Therapeutics funds operations through equity raises and licensing deals — in December 2025, the company licensed a GLP-1R agonist patent portfolio to Genentech for $100M upfront plus royalties, demonstrating a near-term monetization path. The company's long-term model is direct commercialization of its own drugs via physician prescriptions and insurer reimbursement.